Berhampur: Researchers at the Indian Institute of Science Education and Research (IISER), Berhampur, have developed ‘Cisproplatin’ (CPP), a modified version of a widely used chemotherapy drug, which, they claim, could make cancer treatment safer by reducing some of the drug’s most severe side effects.The findings have been published in the latest edition of the Journal of Medicinal Chemistry in a paper authored by Rakesh Kumar Pathak, associate professor, and Kajol, research scholar at IISER Berhampur’s department of chemical sciences, and other IISER Berhampur researchers.Pathak said that the drug has been successfully evaluated in pre-clinical studies, including mouse models.The IISER team said that with further development, manufacturing and clinical testing, CPP could emerge as a made-in-India oncology platform that retains the key drug’s cancer-fighting efficacy while reducing the toxicities that often force doctors to reduce or discontinue treatment. “It is a science-led opportunity for stronger, safer and more resilient Indian oncology innovation,” the researchers said.
